These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34118102)

  • 1. The B-Natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia B.
    Astermark J; Holstein K; Abajas YL; Kearney S; Croteau SE; Liesner R; Funding E; Kempton CL; Acharya S; Lethagen S; LeBeau P; Bowen J; Berntorp E; Shapiro AD
    Haemophilia; 2021 Sep; 27(5):802-813. PubMed ID: 34118102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eradication of FIX inhibitor in haemophilia B children using low-dose immune tolerance induction with rituximab-based immunosuppressive agent(s) in China.
    Li Z; Liu G; Yao W; Chen Z; Li G; Cheng X; Zhen Y; Ai D; Huang K; Sun J; Poon MC; Wu R
    Haemophilia; 2022 Jul; 28(4):625-632. PubMed ID: 35503087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications.
    Kihlberg K; Baghaei F; Bruzelius M; Funding E; Holme PA; Lassila R; Martin M; Nummi V; Ranta S; Strandberg K; Andersson NG; Berntorp E; Astermark J
    Thromb Res; 2022 Sep; 217():22-32. PubMed ID: 35842956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural).
    Shapiro AD; Ragni MV; Borhany M; Abajas YL; Tarantino MD; Holstein K; Croteau SE; Liesner R; Tarango C; Carvalho M; McGuinn C; Funding E; Kempton CL; Bidlingmaier C; Cohen A; Oldenburg J; Kearney S; Knoll C; Kuriakose P; Acharya S; Reiss UM; Kulkarni R; Witkop M; Lethagen S; Donfield S; LeBeau P; Berntorp E; Astermark J
    Haemophilia; 2021 Jan; 27(1):49-59. PubMed ID: 33278853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune tolerance: critical issues of factor dose, purity and treatment complications.
    DiMichele DM
    Haemophilia; 2006 Dec; 12 Suppl 6():81-5; discussion 85-6. PubMed ID: 17123399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study.
    Jiménez-Yuste V; Oldenburg J; Rangarajan S; Peiró-Jordán R; Santagostino E
    Haemophilia; 2016 Nov; 22(6):859-865. PubMed ID: 27329267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.
    Carcao M; Shapiro A; Staber JM; Hwang N; Druzgal C; Lieuw K; Belletrutti M; Thornburg CD; Ahuja SP; Morales-Arias J; Dumont J; Miyasato G; Tsao E; Jain N; Pipe SW
    Haemophilia; 2018 Mar; 24(2):245-252. PubMed ID: 29436077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China.
    Dou X; Zhang W; Poon MC; Zhang X; Wu R; Feng X; Yang L; Cheng P; Chen S; Wang Y; Zhou H; Huang M; Song Y; Jin C; Zhang D; Chen L; Liu W; Zhang L; Xue F; Yang R
    Haemophilia; 2023 Jan; 29(1):123-134. PubMed ID: 36163649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success.
    Elalfy M; Elghamry I; Hassab H; Elalfy O; Andrawes N; El-Ekiaby M
    Haemophilia; 2022 Jan; 28(1):65-72. PubMed ID: 34797008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large deletions and small insertions and deletions in the factor VIII gene predict unfavorable immune tolerance induction outcome in people with severe hemophilia A and high-responding inhibitors.
    Zuccherato LW; Souza RP; Camelo RM; Dias MM; Jardim LL; Santana MAP; Oliveira AG; Lorenzato CS; Cerqueira MH; Franco VKB; Ribeiro RA; Etto LY; Roberti MDRF; Callado FMA; de Cerqueira MAF; Pinto ISS; Garcia AA; Anegawa TH; Neves DCF; Tan DM; Tou RP; Chaves DG; van der Bom J; Rezende SM;
    Thromb Res; 2024 Oct; 242():109115. PubMed ID: 39186847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Japanese Immune Tolerance Induction (J-ITI) study in haemophilia patients with inhibitor: Outcomes and successful predictors of ITI treatment.
    Nogami K; Taki M; Matsushita T; Ohga S; Oka T; Horikoshi Y; Amano K; Shima M
    Haemophilia; 2018 Sep; 24(5):e328-e337. PubMed ID: 29902361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors.
    Kurth MA; Dimichele D; Sexauer C; Sanders JM; Torres M; Zappa SC; Ragni M; Leonard N
    Haemophilia; 2008 Jan; 14(1):50-5. PubMed ID: 17941829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune tolerance induction using a factor VIII/von Willebrand factor concentrate (BIOSTATE), with or without immunosuppression, in Australian paediatric severe haemophilia A patients with high titre inhibitors: a multicentre, retrospective study.
    Robertson JD; Higgins P; Price J; Dunkley S; Barrese G; Curtin J
    Thromb Res; 2014 Nov; 134(5):1046-51. PubMed ID: 25267706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors in haemophilia: what have we learned from registries? A systematic review.
    Osooli M; Berntorp E
    J Intern Med; 2015 Jan; 277(1):1-15. PubMed ID: 25169114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
    Rothschild C; D'Oiron R; Borel-Derlon A; Gruel Y; Navarro R; Negrier C
    Haemophilia; 2013 Mar; 19(2):281-6. PubMed ID: 23038998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune tolerance induction with moroctocog-alpha (Refacto/Refacto AF) in a population of Italian haemophilia A patients with high-titre inhibitors: Data from REF.IT Registry.
    Zanon E; Pasca S; Pollio B; Santagostino E; Linari S; Tagliaferri A; Santoro C; Rocino A; Marino R; Aru B; Borchiellini A; Siragusa S; Coppola A
    Haemophilia; 2019 Nov; 25(6):1003-1010. PubMed ID: 31603594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of the outcome of immune tolerance induction in patients with haemophilia A and inhibitors: The Brazilian Immune Tolerance (BrazIT) Study protocol.
    Camelo RM; Chaves DG; Zuccherato LW; Rezende SM;
    PLoS One; 2021; 16(8):e0256265. PubMed ID: 34437573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late immune tolerance induction in haemophilia A patients.
    Meeks SL; Chapman RL; Kempton C; Dunn AL
    Haemophilia; 2013 May; 19(3):445-8. PubMed ID: 23294063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.